Strategic Consulting
| Year | Client | Period | Income | Expenses | Doc |
|---|---|---|---|---|---|
| 2026 | THE HAYSTACK PROJECT |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | — | |
| 2026 | THE HAYSTACK PROJECT |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | — | |
| 2025 | THE HAYSTACK PROJECT |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
— | — | |
| 2025 | OREXO US, INC. |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Termination (No Activity) |
— | — | |
| 2025 | THE HAYSTACK PROJECT |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
— | — | |
| 2025 | OREXO US, INC. |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report (No Activity) |
— | — | |
| 2025 | THE HAYSTACK PROJECT |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | — | |
| 2025 | OREXO US, INC. |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report (No Activity) |
— | — | |
| 2025 | THE HAYSTACK PROJECT |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | — | |
| 2025 | OREXO US, INC. |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report (No Activity) |
— | — |
| Client | Filings | Total Income |
|---|---|---|
| OREXO US, INC. | 48 | $1,350,000 |
| THE HAYSTACK PROJECT | 37 | — |
| RECORDATI RARE DISEASES | 26 | $440,000 |
| USAGAINSTALHEIMER'S | 15 | $225,000 |
| FCS FOUNDATION | 14 | $160,000 |
| FERRING PHARMACEUTICALS, INC. | 14 | $60,000 |
| USAGINASTALZHEIMER'S NETWORK | 13 | $160,000 |
| AKCEA THERAPEUTICS, INC. | 12 | $190,000 |
| MAST THERAPEUTICS, INC. | 11 | $190,000 |
| ALPHA-1 FOUNDATION | 11 | — |
| IMARA, INC. | 10 | — |
| THERABRON THERAPEUTICS, INC | 8 | $60,000 |
| BINGE EATING DISORDER ASSOCIATION | 7 | — |
| NATIONAL EATING DISORDER ASSOCCIATION | 6 | — |
| STARKEY HEARING TECHNOLOGIES | 5 | $180,000 |
| BIOMARIN PHARMACEUTICAL INC. | 4 | $30,000 |
| Name | Disclosed Prior Position |
|---|---|
| SAIRA SULTAN CHIRICO | US Senate HELP, Employment Subcommittee, Chief Counsel |